Safety and pharmacokinetics of escalating daily doses of the antituberculosis drug rifapentine in healthy volunteers

Clinical Pharmacology and Therapeutics

Volumn 91, Issue 5, 2012, Pages 881-888

  Dooley, K E ^a   Bliven Sizemore, E E ^b   Weiner, M ^c   Lu, Y ^a   Nuermberger, E L ^a   Hubbard, W C ^a   Fuchs, E J ^a   Melia, M T ^a   Burman, W J ^d   Dorman, S E ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d DENVER PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 3A; MIDAZOLAM; RIFAMPICIN; RIFAPENTINE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CONSTIPATION; DIZZINESS; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FEVER; HEADACHE; HUMAN; HYPERBILIRUBINEMIA; HYPERGLYCEMIA; HYPERTRANSAMINASEMIA; LEUKOPENIA; LYMPHOCYTOPENIA; MALE; MAXIMUM TOLERATED DOSE; NEUTROPENIA; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PNEUMATOSIS INTESTINALIS; PRIORITY JOURNAL; SINGLE DRUG DOSE; VOMITING;

ADULT; ANTITUBERCULAR AGENTS; AREA UNDER CURVE; CYTOCHROME P-450 CYP3A; DRUG TOXICITY; FEMALE; HUMANS; MALE; MIDAZOLAM; MIDDLE AGED; RIFAMPIN;

EID: 84859938036     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2011.323     Document Type: Article

References (38)

1. World Health Organization. Global Tuberculosis Control: WHO report 2010 (WHO Press, Geneva, Switzerland, 2010.
2. Bemer-Melchior, P., Bryskier, A. & Drugeon, H.B. Comparison of the in vitro activities of rifapentine and rifampicin against Mycobacterium tuberculosis complex. J. Antimicrob. Chemother. 46, 571-576 (2000).
3. Rosenthal, I.M. et al. Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model. PLoS Med. 4, e344 (2007).
4. Rosenthal, I.M., Zhang, M., Almeida, D., Grosset, J.H. & Nuermberger, E.L. Isoniazid or moxifloxacin in rifapentine-based regimens for experimental tuberculosis? Am. J. Respir. Crit. Care Med. 178, 989-993 (2008).
5. Zhang, M. et al. Treatment of tuberculosis with rifamycin-containing regimens in immune-deficient mice. Am. J. Respir. Crit. Care Med. 183, 1254-1261 (2011).
6. Vernon, A., Burman, W., Benator, D., Khan, A. & Bozeman, L. Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Tuberculosis Trials Consortium. Lancet 353, 1843-1847 (1999).
7. Benator, D. et al.; Tuberculosis Trials Consortium. Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial. Lancet 360, 528-534 (2002).
8. Center for Drug Evaluation and Research, FDA. New- Drug Application 21-024, Rifapentine, by Hoechst Marion Roussel (1998).
9. Vital Durand, D., Hampden, C., Boobis, A.R., Park, B.K. & Davies, D.S. Induction of mixed function oxidase activity in man by rifapentine (MDL 473), a long-acting rifamycin derivative. Br. J. Clin. Pharmacol. 21, 1-7 (1986).
10. Li, A.P. et al. Primary human hepatocytes as a tool for the evaluation of structure-activity relationship in cytochrome P450 induction potential of xenobiotics: evaluation of rifampin, rifapentine and rifabutin. Chem. Biol. Interact. 107, 17-30 (1997).
11. Dooley, K. et al. Repeated administration of high-dose intermittent rifapentine reduces rifapentine and moxifloxacin plasma concentrations. Antimicrob. Agents Chemother. 52, 4037-4042 (2008).
12. Rosenthal, I.M. et al. Potent twice-weekly rifapentine-containing regimens in murine tuberculosis. Am. J. Respir. Crit. Care Med. 174, 94-101 (2006).
13. Grasela, D.M., LaCreta, F.P., Kollia, G.D., Randall, D.M. & Uderman, H.D. Open-label, nonrandomized study of the effects of gatifloxacin on the pharmacokinetics of midazolam in healthy male volunteers. Pharmacotherapy 20, 330-335 (2000).
14. Mathias, A.A., West, S., Hui, J. & Kearney, B.P. Dose-response of ritonavir on hepatic CYP3A activity and elvitegravir oral exposure. Clin. Pharmacol. Ther. 85, 64-70 (2009).
15. Ngo, N. et al. Identification of a cranberry juice product that inhibits enteric CYP3A-mediated first-pass metabolism in humans. Drug Metab. Dispos. 37, 514-522 (2009).
16. Weiner, M. et al. Effects of tuberculosis, race, and human gene SLCO1B1 polymorphisms on rifampin concentrations. Antimicrob. Agents Chemother. 54, 4192-4200 (2010).
17. Burman, W. et al.; Tuberculosis Trials Consortium. Acquired rifamycin resistance with twice-weekly treatment of HIV-related tuberculosis. Am. J. Respir. Crit. Care Med. 173, 350-356 (2006).
18. Benator, D. et al. Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial. Lancet 360, 528-534 (2002).
19. Weiner, M. et al.; Tuberculosis Trials Consortium. Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis. Clin. Infect. Dis. 40, 1481-1491 (2005).
20. Nuermberger, E., Rosenthal, I., Zhang, M. & Grosset, J. Is it possible to cure TB in weeks instead of months? Int. J. Tuberc. Lung Dis. 11 (suppl. 1), S167 (2007).
21. Gumbo, T. et al. Concentration-dependent Mycobacterium tuberculosis killing and prevention of resistance by rifampin. Antimicrob. Agents Chemother. 51, 3781-3788 (2007).
22. Rowland, M. & Tozer, T.N. Dose and time dependencies. In Clinical Pharmacokinetics: Concepts and Applications, Ch. 22, 394-423 (Lippincott, Williams and Wilkins, Philadelphia, PA, 1995).
23. Acocella, G. Clinical pharmacokinetics of rifampicin. Clin. Pharmacokinet. 3, 108-127 (1978).
24. Dorman, S. et al. A phase II study of a rifapentine-containing regimen for intensive phase treatment of pulmonary tuberculosis: preliminary results for Tuberculosis Trials Consortium Study 29: Abstract A6413. American Thoracic Society Annual Meeting, Denver, CO (2011).
25. Langdon, G., Wilkins, J., McFadyen, L., McIlleron, H., Smith, P. & Simonsson, U.S. Population pharmacokinetics of rifapentine and its primary desacetyl metabolite in South African tuberculosis patients. Antimicrob. Agents Chemother. 49, 4429-4436 (2005).
26. Loos, U., Musch, E., Jensen, J.C., Schwabe, H.K. & Eichelbaum, M. Influence of the enzyme induction by rifampicin on its presystemic metabolism. Pharmacol. Ther. 33, 201-204 (1987).
27. Loos, U., Musch, E., Jensen, J.C., Mikus, G., Schwabe, H.K. & Eichelbaum, M. Pharmacokinetics of oral and intravenous rifampicin during chronic administration. Klin. Wochenschr. 63, 1205-1211 (1985).
28. Chen, J. & Raymond, K. Roles of rifampicin in drug-drug interactions: underlying molecular mechanisms involving the nuclear pregnane X receptor. Ann. Clin. Microbiol. Antimicrob. 5, 3 (2006).
29. Martin, P., Riley, R., Back, D.J. & Owen, A. Comparison of the induction profile for drug disposition proteins by typical nuclear receptor activators in human hepatic and intestinal cells. Br. J. Pharmacol. 153, 805-819 (2008).
30. Xu, C., Wang, X. & Staudinger, J.L. Regulation of tissue-specific carboxylesterase expression by pregnane x receptor and constitutive androstane receptor. Drug Metab. Dispos. 37, 1539-1547 (2009).
31. Acocella, G., Mattiussi, R. & Segre, G. Multicompartmental analysis of serum, urine and bile concentrations of rifampicin and desacetyl-rifampicin in subjects treated for one week. Pharmacol. Res. Commun. 10, 271-288 (1978).
32. Watkins, P.B. Noninvasive tests of CYP3A enzymes. Pharmacogenetics 4, 171-184 (1994).
33. Tsunoda, S.M., Velez, R.L., von Moltke, L.L. & Greenblatt, D.J. Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: effect of ketoconazole. Clin. Pharmacol. Ther. 66, 461-471 (1999).
34. US Department of Health and Human Services. Guidance for Industry. In Vivo Drug Metabolism/Drug Interaction Studies: Study Design, Data Analysis, and Recommendations for Dosing and Labelling. 2009 (2012).
35. Backman, J.T., Olkkola, K.T. & Neuvonen, P.J. Rifampin drastically reduces plasma concentrations and effects of oral midazolam. Clin. Pharmacol. Ther. 59, 7-13 (1996).
36. Chung, E., Nafziger, A.N., Kazierad, D.J. & Bertino, J.S. Jr. Comparison of midazolam and simvastatin as cytochrome P450 3A probes. Clin. Pharmacol. Ther. 79, 350-361 (2006).
37. de Velde, F., Alffenaar, J.W., Wessels, A.M., Greijdanus, B. & Uges, D.R. Simultaneous determination of clarithromycin, rifampicin and their main metabolites in human plasma by liquid chromatography-tandem mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 877, 1771-1777 (2009).
38. Dumond, J.B. et al. A phenotype-genotype approach to predicting CYP450 and P-glycoprotein drug interactions with the mixed inhibitor/inducer tipranavir/ritonavir. Clin. Pharmacol. Ther. 87, 735-742 (2010).